Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05358249 · ClinicalTrials.gov registry record · Phase 1

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

A Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Novartis Pharmaceuticals.

Active
Registry status
Phase 1
Development phase
74
Enrollment target
13
Study locations

NCT05358249 is a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 74 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The trial reports 13 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05358249, a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
74 participants
Enrollment target
13
Study locations

Study Summary

This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.

Conditions Studied

Non-Small Cell Lung Cancer Colorectal Cancer Carcinoma, Non-Small Cell Lung Colorectal Neoplasms Colorectal Carcinoma Non-Small-Cell Lung Carcinoma Nonsmall Cell Lung Cancer Colorectal Tumors KRAS G12C Mutant Solid Tumors

Interventions

  • DRUG trametinib
  • DRUG Ribociclib
  • BIOLOGICAL cetuximab
  • DRUG JDQ443

Study Locations (13)

Other

  • Novartis Investigative Site - Leuven
  • Novartis Investigative Site - Bordeaux
  • Novartis Investigative Site - Lyon
  • Novartis Investigative Site - Singapore
  • Novartis Investigative Site - Barcelona
  • Novartis Investigative Site - Madrid
  • Novartis Investigative Site - Madrid

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana Farber Cancer Institute - Boston

New York

  • NYU School of Medicine - New York

Baden-Wurttemberg

  • Novartis Investigative Site - Freiburg im Breisgau

MI

  • Novartis Investigative Site - Milan

Korea

  • Novartis Investigative Site - Seoul

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2022-10-24
Est. Completion 2026-11-30
Phase Phase 1

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05358249

The ClinicalTrials.gov registry entry for NCT05358249 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 9 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which trametinib is the first listed.

NCT05358249 reports 13 study locations spanning 6 distinct geographic areas - top geographies include Other, Massachusetts, New York.

Frequently Asked Questions

What is clinical trial NCT05358249 about?

NCT05358249 is a clinical study titled "Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation". This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.

What is the current status of trial NCT05358249?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2022-10-24. Estimated completion is 2026-11-30.

What conditions does trial NCT05358249 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Carcinoma, Non-Small Cell Lung, Colorectal Neoplasms, Colorectal Carcinoma.

What interventions are being tested in trial NCT05358249?

The interventions under investigation include: trametinib (DRUG), Ribociclib (DRUG), cetuximab (BIOLOGICAL), JDQ443 (DRUG).

Who is sponsoring clinical trial NCT05358249?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05358249 being conducted?

This trial has 13 study locations across Massachusetts, New York, Baden-Wurttemberg, MI, Korea. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Colorectal Cancer

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.